Genetic testing in patients with triple-negative or hereditary breast cancer.
Journal
Current opinion in oncology
ISSN: 1531-703X
Titre abrégé: Curr Opin Oncol
Pays: United States
ID NLM: 9007265
Informations de publication
Date de publication:
01 11 2021
01 11 2021
Historique:
pubmed:
3
9
2021
medline:
25
11
2021
entrez:
2
9
2021
Statut:
ppublish
Résumé
In recent years there has been a dramatic evolution in the clinical utility of genetic testing with expanding therapeutic implications for individuals with breast cancer who harbor a germline mutation in BRCA1/2. As these therapeutic opportunities expand and evolve, this requires the clinical and research community to rethink the approach to genetic testing for individuals with breast cancer. Genetic testing is evolving from traditional testing models based on pretest counseling with the aim of identifying hereditary and individual risk for purposes of screening and risk reduction to contemporary models that utilize technology to improve accessibility and oncology led mainstreaming of testing where the oncologist refers for genetic testing, discloses the results and formal counseling occurs later in the process than in traditional models. The cost and accessibility to multigene panel testing have resulted in broad uptake despite the fact that clinical utility and appropriate interpretation of results are not yet well established. Furthermore, somatic testing for genomic alterations may also yield results beyond the disease with detection of germline mutations impacting the individual and their family more broadly than anticipated. With the establishment of poly (adenosine diphosphate-ribose) polymerase inhibitors as part of the treatment armamentarium for early and advanced breast cancer, paradigms, algorithms, and resources for genetic testing need to rapidly change in order to adapt to the evolution of germline mutations from hereditary and individual risk predictors to predictive therapeutic biomarkers.
Identifiants
pubmed: 34474437
doi: 10.1097/CCO.0000000000000784
pii: 00001622-202111000-00007
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
584-590Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Hu C, Hart SN, Gnanaolivu R, et al. A population-based study of genes previously implicated in breast cancer. N Engl J Med 2021; 384:440–451.
Consortium BCA. Breast cancer risk genes — association analysis in more than 113,000 women. N Engl J Med 2021; 384:428–439.
Tung N, Lin NU, Kidd J, et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol 2016; 34:1460–1468.
Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017; 317:2402–2416.
Comprehensive molecular portraits of human breast tumors. Nature 2012; 490:61–70.
Kurian AW, Ward KC, Hamilton AS, et al. Uptake, results, and outcomes of germline multiple-gene sequencing after diagnosis of breast cancer. JAMA Oncol 2018; 4:1066–1072.
Beitsch PD, Whitworth PW, Hughes K, et al. Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol 2019; 37:453–460.
Ellsworth DL, Turner CE, Ellsworth RE. A review of the hereditary component of triple negative breast cancer: high- and moderate-penetrance breast cancer genes, low-penetrance loci, and the role of nontraditional genetic elements. J Oncol 2019; 2019:4382606.
Tung NM, Robson ME, Ventz S, et al. TBCRC 048: Phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J Clin Oncol 2020; 38:4274–4282.
Trepanier AM, Allain DC. Models of service delivery for cancer genetic risk assessment and counseling. J Genet Couns 2014; 23:239–253.
Patel M, Nowsheen S, Maraboyina S, Xia F. The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review. Cell Biosci 2020; 10:35.
Abacan M, Alsubaie L, Barlow-Stewart K, et al. The global state of the genetic counseling profession. Eur J Hum Genet 2019; 27:183–197.
Biesecker B. Genetic counseling and the central tenets of practice. Cold Spring Harb Perspect Med 2020; 10:a038968.
Greenberg SE, Boothe E, Delaney CL, et al. Genetic counseling service delivery models in the United States: assessment of changes in use from 2010 to 2012. J Genet Couns 2020; 29:1126–1141.
Hallquist MLG, Tricou EP, Hallquist MN, et al. Positive impact of genetic counseling assistants on genetic counseling efficiency, patient volume, and cost in a cancer genetics clinic. Genet Med 2020; 22:1348–1354.
Scott N, O'Sullivan J, Asgeirsson K, et al. Changing practice: moving to a specialist nurse-led service for BRCA gene testing. Br J Nurs 2020; 29:S6–13.
Piedimonte S, Power J, Foulkes WD, et al. BRCA testing in women with high-grade serous ovarian cancer: gynecologic oncologist-initiated testing compared with genetics referral. Int J Gynecol Cancer 2020; 30:1757–1761.
Rumford M, Lythgoe M, McNeish I, et al. Oncologist-led BRCA ‘mainstreaming’ in the ovarian cancer clinic: A study of 255 patients and its impact on their management. Sci Rep 2020; 10:3390.
Kemp Z, Turnbull A, Yost S, et al. Evaluation of cancer-based criteria for use in mainstream BRCA1 and BRCA2 genetic testing in patients with breast cancer. JAMA Network Open 2019; 2:e194428–e1194428.
Beard C, Monohan K, Cicciarelli L, James PA. Mainstream genetic testing for breast cancer patients: early experiences from the Parkville Familial Cancer Centre. Eur J Hum Genet 2021; 29:872–880.
Pal T, Agnese D, Daly M, et al. Points to consider: is there evidence to support BRCA1/2 and other inherited breast cancer genetic testing for all breast cancer patients? A statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2020; 22:681–685.
Robson M, Domchek S. Broad application of multigene panel testing for breast cancer susceptibility—Pandora's box is opening wider. JAMA Oncol 2019; 5:1687.
White S, Jacobs C, Phillips J. Mainstreaming genetics and genomics: a systematic review of the barriers and facilitators for nurses and physicians in secondary and tertiary care. Genet Med 2020; 22:1149–1155.
Gleeson M, Kentwell M, Meiser B, et al. The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients. Gynecol Oncol 2020; 158:431–439.
George A, Turnbull C. Tumor-only sequencing for oncology management: germline-focused analysis and implications. Genes Chromosom Cancer 2021; 60:352–357.
McCuaig JM, Armel SR, Care M, et al. Next-generation service delivery: a scoping review of patient outcomes associated with alternative models of genetic counseling and genetic testing for hereditary cancer. Cancers 2018; 10:435.
Konstantinopoulos PA, Norquist B, Lacchetti C, et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. JCO Oncol Pract 2020; 16:e835–e838.
Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 30:1194–1220.
Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer | Guidance and guidelines | NICE [Internet]. [cited 2019 Feb 1]. Available from: https://www.nice.org.uk/guidance/cg164
Daly MB, Reiser G, Pal T, et al. NCCN guidelines index table of contents genetic/familial high-risk assessment: breast, ovarian, and pancreatic discussion. Risk Assess 2020; 122.
Tung NM, Boughey JC, Pierce LJ, et al. Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. JCO 2020; 38:2080–2106.
Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA Mutation. N Engl J Med 2018; 379:753–763.
Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol 2019; 30:558–566.
Vikas P, Borcherding N, Chennamadhavuni A, Garje R. Therapeutic potential of combining PARP inhibitor and immunotherapy in solid tumors. Front Oncol 2020; 10:570.
Manahan ER, Kuerer HM, Sebastian M, et al. Consensus guidelines on genetic‘ testing for hereditary breast cancer from the American Society of Breast Surgeons. Ann Surg Oncol 2019; 26:3025–3031.
Sun L, Brentnall A, Patel S, et al. A cost-effectiveness analysis of multigene testing for all patients with breast cancer. JAMA Oncol 2019; 5:1718–1730.
Samadder NJ, Riegert-Johnson D, Boardman L, et al. Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome. JAMA Oncol 2021; 7:230–237.
Manchanda R, Patel S, Gordeev VS, et al. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation testing in unselected general population women. J Natl Cancer Inst 2018; 110:714–725.
Manchanda R, Lieberman S, Gaba F, et al. Population screening for inherited predisposition to breast and ovarian cancer. Annu Rev Genom Hum Genet 2020; 21:373–412.
Tendl KA, Bago-Horvath Z. Molecular profiling in breast cancer—ready for clinical routine? memo 2020; 13:445–449.
Sivapiragasam A, Kumar PA, Sokol ES, et al. Predictive biomarkers for immune checkpoint inhibitors in metastatic breast cancer. Cancer Med 2021; 10:53–61.
Mandelker D, Donoghue M, Talukdar S, et al. Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group. Ann Oncol 2019; 30:1221–1231.
Petrucelli N, Daly MB, Feldman GL. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med 2010; 12:245–259.
Mavaddat N, Peock S, Frost D, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013; 105:812–822.
Wong-Brown MW, Meldrum CJ, Carpenter JE, et al. Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res Treat 2015; 150:71–80.
Chen H, Wu J, Zhang Z, et al. Association between BRCA status and triple-negative breast cancer: a meta-analysis. Front Pharmacol 2018; 9:909.
Spurdle AB, Couch FJ, Parsons MT, et al. Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Res 2014; 16:3419.
Zhou J, Wang H, Fu F, et al. Spectrum of PALB2 germline mutations and characteristics of PALB2-related breast cancer: Screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing. Cancer 2020; 126:3202–3208.
Bergstrom C, Pence C, Berg J, et al. Clinicopathological features and outcomes in individuals with breast cancer and ATM, CHEK2, or PALB2 mutations. Ann Surg Oncol 2020; 28:3383–3393.
Marabelli M, Cheng S-C, Parmigiani G. Penetrance of ATM gene mutations in breast cancer: a meta-analysis of different measures of risk. Genet Epidemiol 2016; 40:425–431.
Hansford S, Kaurah P, Li-Chang H, et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol 2015; 1:23.
Figueiredo J, Melo S, Carneiro P, et al. Clinical spectrum and pleiotropic nature of CDH1 germline mutations. J Med Genet 2019; 56:199–208.
Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250:1233–1238.
Ruijs MW, Verhoef S, Rookus MA, et al. TP53 germline mutation testing in 180 families suspected of Li–Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet 2010; 47:421–428.
Wilson JRF, Bateman AC, Hanson H, et al. A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. J Med Genet 2010; 47:771–774.
Bougeard G, Renaux-Petel M, Flaman JM, et al. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol 2015; 33:2345–2352.
Tchekmedyian A, Amos CI, Bale SJ, et al. Findings from the Peutz-Jeghers syndrome registry of uruguay. PLoS One 2013; 8:e79639.
Nelen MR, Kremer H, Konings IB, Schoute F. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype–phenotype correlations. Eur J Hum Genet 1999; 7:267–273.
Bubien V, Bonnet F, Brouste V, et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet 2013; 50:255–263.
Byrski T, Huzarski T, Dent R, et al. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2014; 147:401–405.
Poggio F, Bruzzone M, Ceppi M, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol 2018; 29:1497–1508.
Tutt A, Tovey H, Cheang MCU, et al. A randomised phase III trial of carboplatin compared with docetaxel in BRCA1/2 mutated and prespecified triple negative breast cancer ‘BRCAness’ subgroups: the TNT Trial. Nat Med 2018; 24:628–637.
Robson M, Im S-A, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017; 377:523–533.
Diéras V, Han HS, Kaufman B, et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2020; 21:1269–1282.
Tutt A, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 2021; 384:2394–2405.
Litton JK, Scoggins ME, Whitman GJ, et al. A feasibility study of neoadjuvant talazoparib for early-stage breast cancer patients with a germline BRCA pathogenic variant: NCT02282345.| J Clin Oncol [Internet]. [cited 2021 Apr 28]. Available from: https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.TPS595
Litton JK, Scoggins ME, Hess KR, et al. Neoadjuvant talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant. J Clin Oncol 2020; 38:388–394.
Fasching PA, Link T, Hauke J, et al. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Ann Oncol 2021; 32:49–57.